Injectable Anticoagulant Substantially Cuts Bleeding Risk in Afib
Med Page Today
JANUARY 23, 2025
(MedPage Today) -- For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), according to the AZALEA.
Let's personalize your content